London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's a gamble, we all know that. £7 will need good toxicity and dosing results, funding through to end of phase 1 and maybe a bit of news on 737. All doable.
What a week... go away for a few days and look what happens!!!
real 5hteshow...
Sad - I was under the impression that they had to prove funding was available prior to any trials starting, so we must be fully funded for P1a?
but after this weeks performance WTFDIK...
Robin hood. Massive risk but £7 a share give him/her a million profit. They might do more than most here have done in 10 years, in a few short months. No one chucks £37k away so I guess there is a level of confidence or even know something. 🤔
20p on the bid now too PUMA.
"Topline results" are not due until Q2 2024, according to last Tuesday's RNS. So, we could be looking at June at the latest. I just hope some positive news re: financing is released sooner than that, otherwise God help the sp.
No not at all, this profile is older than his was.
Sareum will still have to pay research fees. There is also health checks carried out after completion of trial for several weeks and this data needs collecting and collating. Not cheap at all.
Most likely looking around 6 weeks minimum after last dosing before we get final results.
Biomarker data will require analysis. All time consuming and costly.
Generally a phase 1 trial costs around 4 million dollars.
Regards
Replace development with research
.. Research keeping on despite more than critical finances and spend to expensive (outsourced) 3rdP.
I am just lost for words. Having had a loss of 3.5 M£ at YE2023 or end of June 2023 company expects to report an operating loss of £2.5 million (2022: £1.7 million) i.e. in a half period of time.
Development keeping on despite more than critical finances and spend to expensive (outsourced) 3rdP. The Bod just cannot stop wasting money instead of awaiting the results first but is unable to put any further expenditure on hold. If that is not disgusting.
Well, to be fair. The SP isn't going to go up until we get clarity on the the state of the company finances. Its as simple as that. We might have to wait until the interim results are out for that.
The RNS looks to have bolstered the Sp from falling further, a slight reduction today, but most positions in other stocks are suffering a little today. A couple more £36k trades would start to suggest somebody knows something we don't.... or perhaps even a director deal about now, that would do the trick
... a bit of good news the SP goes down.
Uncanny!!
Indeed TraderMatt - I wish I had to funds to buy a similar sized whopper, but have had a modest top up today, another to follow next week when I have freed up some more funds.
Keep the faith.
Somebody has some, delayed trade fairly chunky one
Wish mine was!!!
(Need c.£2.55 just to break even! 😢)
Ratty, you still spending the occasional night in the tarpaulin covered skip outside Sareum HQ in Pampisford?
Good to hear from you, been a few years.
Regards
Hi C79 - I'm not sure NuMedii fits the bill as they seem more about using AI and Big Data to look for new treatments in general rather than being the "...company that is committed to advancing promising oncology programmes." (That's a quote from the answer to Q19 from the Dec AGM.)
As for ProLynx, an interesting possibility if they went for a triple combo e.g. 737+PLX038+chemo. Perhaps one to watch.
Regards.
This is a good read https://www.edisongroup.com/research/sdc-1801-embarks-on-clinical-journey-in-fy23/32763/
Despite the negative RNS relating to funding there are a few possibilities for raising funds:
HNWI’s
A major purchasing a stake in Sareum
Open book raise to include shareholders
Shareholder action
Saudi Investment as per their stated ambitions to become a centre of excellence for leading edge medical science and medicines.
737.
I have no idea how it will play out but there are options. Also the RNS suggested that wheels were already in motion.
A long way to go but we are far from being skewered. We just need the plan B confirming.
Also worth mentioning that there are only circa 72m shares issued so plenty of headroom
Well JJ; whatever floats your boat.😂
Uncannily similar! I wanted to buy a 8t 360 excavator, I could easily have afforded it and a trailer if I'd sold in 2020